Antisense technology is going through an analogous technological evolution, albeit with less success so far. The main weakness of the first and second generation of antisense drugs developed by Isis Pharmaceuticals and Genta is the lack of potency. Much excitement still lies in the third generation of antisense drugs having greater RNA-binding affinity. Validation of antisense technology has yet to be achieved and time will soon tell whether it is truly worth the hype.